Key Points
- Director Hongbo Lu sold 2,970 shares of Arrowhead Pharmaceuticals at an average price of $76.88, a $228,333 transaction. The sale was made under a pre-arranged Rule 10b5-1 plan, and Lu still holds 52,012 shares.
- Arrowhead recently beat earnings expectations for the quarter, reporting an EPS loss of $0.93 versus the expected $1.10 loss. However, revenue came in roughly in line with estimates and was still sharply below year-ago levels.
- Analyst sentiment remains broadly positive, with several firms raising price targets and ratings. Notably, RBC set an $87 target, JPMorgan started coverage with an $88 target, and the consensus rating is currently Moderate Buy.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) Director Hongbo Lu sold 2,970 shares of the business's stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director owned 52,012 shares in the company, valued at $3,998,682.56. The trade was a 5.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arrowhead Pharmaceuticals Price Performance
ARWR stock opened at $79.69 on Friday. The firm's 50-day moving average price is $65.71 and its two-hundred day moving average price is $61.75. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $14.30 and a 12-month high of $82.26. The stock has a market capitalization of $11.23 billion, a price-to-earnings ratio of -37.06 and a beta of 1.28. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 1.41.
Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm had revenue of $73.74 million for the quarter, compared to analysts' expectations of $73.84 million. During the same quarter in the previous year, the company earned $2.75 earnings per share. The company's revenue for the quarter was down 86.4% compared to the same quarter last year. As a group, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.97 earnings per share for the current year.
Institutional Investors Weigh In On Arrowhead Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Arrowhead Pharmaceuticals by 3.3% during the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company's stock valued at $553,077,000 after buying an additional 510,798 shares during the last quarter. Avoro Capital Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 2.8% during the third quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company's stock valued at $375,941,000 after buying an additional 300,000 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company's stock valued at $216,799,000 after buying an additional 133,921 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Arrowhead Pharmaceuticals by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company's stock valued at $144,441,000 after buying an additional 504,883 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Arrowhead Pharmaceuticals by 0.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,087,953 shares of the biotechnology company's stock valued at $138,619,000 after buying an additional 6,264 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.
Arrowhead Pharmaceuticals News Summary
Here are the key news stories impacting Arrowhead Pharmaceuticals this week:
- Positive Sentiment: Arrowhead announced a global license and collaboration agreement with Sarepta Therapeutics for multiple clinical and preclinical programs, a potentially meaningful pipeline expansion that could improve future commercialization prospects. Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs
- Positive Sentiment: HC Wainwright maintained a Buy rating and $100 price target while lifting some longer-term earnings estimates, reinforcing a bullish stance on Arrowhead’s future growth.
- Positive Sentiment: Sanford C. Bernstein raised its price target on Arrowhead from $35 to $46, signaling improved confidence even though its rating remains only market perform.
- Neutral Sentiment: Arrowhead presented at the Bank of America Global Healthcare Conference, but no major new clinical or financial update was included in the transcript headline. Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Neutral Sentiment: HC Wainwright made only small mixed changes to its earnings forecasts for 2026-2027, which may affect sentiment but do not materially alter the overall bullish thesis.
- Neutral Sentiment: Director Hongbo Lu sold 2,970 shares in a pre-arranged 10b5-1 transaction; because it was planned and relatively small versus his holdings, it is not a strong negative signal on its own.
Analyst Ratings Changes
Several equities analysts recently issued reports on ARWR shares. Royal Bank Of Canada boosted their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an "outperform" rating in a research report on Friday, May 8th. Sanford C. Bernstein boosted their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the company a "market perform" rating in a research report on Wednesday. JPMorgan Chase & Co. started coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They set an "overweight" rating and a $88.00 price target on the stock. Weiss Ratings reiterated a "hold (c-)" rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, May 6th. Finally, B. Riley Financial upped their price objective on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a "buy" rating in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $87.80.
View Our Latest Research Report on Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals Company Profile
(
Get Free Report)
Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.
The company's pipeline includes multiple candidates in various stages of development.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
